Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.70017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Lijun Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, The First Clinical Medical College of Nanjing Medical Universi…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Phenylurea Compounds, Pyridines, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: This study was supported by National Natural Science Foundation of China (82273197) and Key project of Science and technology in Jiangsu Province (BG2024007)..
Abstract (Originalsprache)
Despite notable advancements in therapeutic modalities, many patients with colorectal cancer (CRC) exhibit inadequate response to regorafenib, largely due to the propensity for drug resistance. Deeper insights into the mechanism of CRC sensitivity to regorafenib therapy are urgently required. The antiapoptotic protein B‐cell lymphoma 2 (BCL‐2) is closely associated with a variety of malignancies. Therefore, this study investigated the role of BCL‐2 in promoting regorafenib resistance in colorectal cancer. Venetoclax, a BCL‐2 antagonist, potentiates the antitumor activity of regorafenib. The combination of regorafenib and Venetoclax inhibited the proliferation and promoted apoptosis of CRC cells and human umbilical vein endothelial cells in vitro by inhibiting tumor angiogenesis, promoting normalization of tumor blood vessels, and promoting immune cell infiltration and the release of immune cytotoxic factors. Although Venetoclax is primarily used clinically to treat hematological tumors, it has not yet been used to treat CRC. These findings provide new insights for the clinical treatment of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, The First Clinical Medical College of Nanjing Medical University, Nanjing Medical University, Nanjing, China.
- Department of Oncology, Northern Jiangsu People's Hospital, Yangzhou, China.
- Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
- State Key Laboratory of Pharmaceutical Biotechnology, Department of Gastroenterology, Nanjing Drum Tower Hospital, School of Life Science, Nanjing University, Nanjing, People's Republic of China.
ORCID-Profile: Yanhong Gu
Förderung
- This study was supported by National Natural Science Foundation of China (82273197) and Key project of Science and technology in Jiangsu Province (BG2024007).
Zitieren
APA
Zhu, L., Wang, W., Dong, Y., Han, X., Zhang, W., Zhang, Z., Guo, W., & Gu, Y. (2025). Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70017
Vancouver
Zhu L, Wang W, Dong Y, Han X, Zhang W, Zhang Z, et al. Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2. Molecular Carcinogenesis. 2025. doi:10.1002/mc.70017
BibTeX
@article{Zhu2025,
author = {Zhu, Lijun and Wang, Weicheng and Dong, Yuwen and Han, Xiao and Zhang, Wei and Zhang, Zhonghua and Guo, Wenjie and Gu, Yanhong},
title = {Venetoclax Synergizes With Regorafenib for Colorectal Cancer by Targeting BCL‐2},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.70017}
}
EUVIMED